tirzepatide is a once-weekly glucose-dependent insulin-stimulating polypeptide receptor and glucagon-like peptide-1 (GLP-1) receptor dual agonist developed by Eli Lilly. Both GIP and GLP-1 are secreted hormones in the gut that promote insulin secretion (source references)
